Oppenheimer Asset Management’s Sage Therapeutics SAGE Stock Holding History

Oppenheimer Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,568	Closed	-$113K	–	1617
2019 Q4	$113K	Sell	1,568 -2,929	-65%	-$360K	﹤0.01%	1170
2019 Q3	$631K	Sell	4,497 -225	-5%	-$37.6K	0.01%	746
2019 Q2	$865K	Sell	4,722 -143	-3%	-$24.4K	0.02%	662
2019 Q1	$774K	Buy	4,865 +874	+22%	+$127K	0.02%	678
2018 Q4	$382K	Sell	3,991 -328	-8%	-$37.5K	0.01%	837
2018 Q3	$610K	Buy	4,319 +377	+10%	+$58.2K	0.01%	756
2018 Q2	$617K	Buy	3,942 +1,860	+89%	+$292K	0.02%	733
2018 Q1	$335K	Buy	+2,082	New	+$353K	0.01%	902
2017 Q4	–	Sell	-1,944	Closed	-$122K	–	1407
2017 Q3	$122K	Buy	1,944 +1,565	+413%	+$123K	﹤0.01%	1151
2017 Q2	$30K	Sell	379 -4	-1%	-$289	﹤0.01%	1442
2017 Q1	$27K	Buy	+383	New	+$22.4K	﹤0.01%	1441

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Oppenheimer Asset Management's SAGE Position: Q1 2020 in Review

Oppenheimer Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 1,568 shares — an estimated $113K sold.

Oppenheimer Asset Management first reported a position in SAGE in Q1 2017 and held it in 11 quarters. The position peaked at $865K in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

Oppenheimer Asset Management reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
Oppenheimer Asset Management sold 1,568 Sage Therapeutics shares in Q1 2020, an estimated $113K.
Oppenheimer Asset Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 11 quarters.
Oppenheimer Asset Management's Sage Therapeutics position peaked at $865K in Q2 2019.
230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Oppenheimer Asset Management's 13F filing for Q1 2020, filed 8 May 2020.